ES2184106T3 - Utilizacion del derivado de k-252a en el tratamiento de trastornos del sistema nervioso periferico o central, y de la hiperproduccion de citoquinas. - Google Patents

Utilizacion del derivado de k-252a en el tratamiento de trastornos del sistema nervioso periferico o central, y de la hiperproduccion de citoquinas.

Info

Publication number: ES2184106T3
Authority: ES; Spain
Prior art keywords: derivative; hyperproduction; cytokines; peripheral; treatment
Prior art date: 1996-06-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES97930203T

Other languages

English (en)

Spanish (es)

Inventor

Thomas M Engber

Forrest A Haun

Michael S Saporito

Lisa D Aimone

Matthew S Miller

Ernest Knight Jr

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cephalon LLC

Original Assignee

Cephalon LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-25

Filing date

1997-06-24

Publication date

2003-04-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21798468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2184106(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-06-24 Application filed by Cephalon LLC filed Critical Cephalon LLC

2003-04-01 Application granted granted Critical

2003-04-01 Publication of ES2184106T3 publication Critical patent/ES2184106T3/es

2017-06-24 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Otolaryngology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ES97930203T 1996-06-25 1997-06-24 Utilizacion del derivado de k-252a en el tratamiento de trastornos del sistema nervioso periferico o central, y de la hiperproduccion de citoquinas. Expired - Lifetime ES2184106T3 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US2040696P	1996-06-25	1996-06-25

Publications (1)

Publication Number	Publication Date
ES2184106T3 true ES2184106T3 (es)	2003-04-01

Family

ID=21798468

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES97930203T Expired - Lifetime ES2184106T3 (es)	1996-06-25	1997-06-24	Utilizacion del derivado de k-252a en el tratamiento de trastornos del sistema nervioso periferico o central, y de la hiperproduccion de citoquinas.

Country Status (16)

Country	Link
US (1)	US6184217B1 (2)
EP (1)	EP0912184B1 (2)
JP (2)	JP2000514420A (2)
CN (1)	CN1108799C (2)
AT (1)	ATE224718T1 (2)
AU (1)	AU721942B2 (2)
BR (1)	BR9710693A (2)
DE (1)	DE69715862T2 (2)
DK (1)	DK0912184T3 (2)
ES (1)	ES2184106T3 (2)
NO (1)	NO317335B1 (2)
NZ (1)	NZ333441A (2)
PT (1)	PT912184E (2)
RU (1)	RU2183959C2 (2)
UA (1)	UA65542C2 (2)
WO (1)	WO1997049406A1 (2)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6127401A (en) *	1998-06-05	2000-10-03	Cephalon, Inc.	Bridged indenopyrrolocarbazoles
US6200968B1 (en) *	1998-08-06	2001-03-13	Cephalon, Inc.	Particle-forming compositions containing fused pyrrolocarbazoles
WO2000018407A1 (en)	1998-09-25	2000-04-06	Cephalon, Inc.	Methods for preventing/treating damage to sensory hair cells and cochlear neurons
CA2347519A1 (en)	1998-10-13	2000-04-20	Kyowa Hakko Kogyo Co., Ltd.	An agent for treating ophthalmopathy
JP2000290184A (ja) *	1999-04-01	2000-10-17	Kyowa Hakko Kogyo Co Ltd	経鼻投与製剤
WO2001051046A1 (en) *	2000-01-14	2001-07-19	University Of Virginia Patent Foundation	Airway alkalinization as therapy for airway diseases
WO2001085151A2 (en) *	2000-05-08	2001-11-15	Psoriasis Research Institute	Chimeric animal model and treatment of psoriasis
US7129250B2 (en)	2000-05-19	2006-10-31	Aegera Therapeutics Inc.	Neuroprotective and anti-proliferative compounds
US7018999B2 (en)	2001-05-16	2006-03-28	Cephalon, Inc.	Methods for the treatment and prevention of pain
NZ540879A (en) *	2002-12-23	2008-08-29	Rinat Neuroscience Corp	Methods for treating taxol-induced sensory neuropathy
WO2004085648A2 (en)	2003-03-19	2004-10-07	Biogen Idec Ma Inc.	Nogo receptor binding protein
EP1620127A4 (en) *	2003-03-20	2007-04-04	Rinat Neuroscience Corp	METHOD FOR TREATING TAXOL-INDUCED ANTI-FERROUS DISORDER
TWI324604B (en) *	2003-06-18	2010-05-11	Novartis Ag	New use of staurosporine derivatives
WO2005007144A2 (en) *	2003-07-14	2005-01-27	Decode Genetics Ehf	Method of diagnosis and treatment for asthma based on haplotype association
US20060014165A1 (en) *	2003-07-14	2006-01-19	Decode Genetics Ehf.	Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
US20060210553A1 (en) *	2003-07-23	2006-09-21	Creabilis Therapeutics S.R.L.	Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excesssive cell proliferation
AU2005217024B2 (en)	2004-02-27	2011-03-24	Cephalon, Inc.	Crystalline forms of a pharmaceutical compound
PT1776136E (pt)	2004-06-24	2012-12-05	Biogen Idec Inc	Tratamento de estados que envolvem desmielinização
MX2007001155A (es) *	2004-07-29	2007-08-14	Creabilis Therapeutics Spa	Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
AR054260A1 (es) *	2005-04-26	2007-06-13	Rinat Neuroscience Corp	Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
SI1904104T1 (sl)	2005-07-08	2013-12-31	Biogen Idec Ma Inc.	Protitelesa SP35 in njihova uporaba
JP2009544703A (ja) *	2006-07-24	2009-12-17	バイオジェン・アイデック・エムエイ・インコーポレイテッド	Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法
DK2982695T3 (da)	2008-07-09	2019-05-13	Biogen Ma Inc	Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
CN104470541A (zh)	2012-05-14	2015-03-25	比奥根艾迪克Ma公司	用于治疗涉及运动神经元的疾患的lingo-2拮抗剂
JP2018504400A (ja)	2015-01-08	2018-02-15	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6041489A (ja) *	1983-08-12	1985-03-05	Kyowa Hakko Kogyo Co Ltd	新規生理活性物質ｋ―２５２
US4554402A (en)	1983-12-23	1985-11-19	Aluminum Company Of America	Vibration damper for overhead conductor
JPS62120388A (ja)	1985-11-19	1987-06-01	Meiji Seika Kaisha Ltd	Ｓｆ−２３７０物質ハロゲン化誘導体とその製造法
JPS62155284A (ja)	1985-12-27	1987-07-10	Kyowa Hakko Kogyo Co Ltd	生理活性物質ｋ−２５２の誘導体
JPS62155285A (ja)	1985-12-27	1987-07-10	Kyowa Hakko Kogyo Co Ltd	生理活性物質ｋ−２５２の誘導体
JPS62220196A (ja)	1986-03-20	1987-09-28	Kyowa Hakko Kogyo Co Ltd	新規物質ｕｃｎ―０１
US4816450A (en)	1986-09-15	1989-03-28	Duke University	Inhibition of protein kinase C by long-chain bases
JPH0826036B2 (ja)	1987-01-22	1996-03-13	協和醗酵工業株式会社	生理活性物質ｋ−２５２の誘導体
US4735939A (en)	1987-02-27	1988-04-05	The Dow Chemical Company	Insecticidal activity of staurosporine
DE3752123T2 (de)	1987-03-09	1998-05-14	Kyowa Hakko Kogyo Kk	Derivate des physiologisch aktiven mittels k-252
IL86632A0 (en)	1987-06-15	1988-11-30	Ciba Geigy Ag	Derivatives substituted at methyl-amino nitrogen
US5093330A (en)	1987-06-15	1992-03-03	Ciba-Geigy Corporation	Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) *	1987-12-24	1995-12-06	協和醗酵工業株式会社	Ｋ−２５２誘導体
WO1989007105A1 (fr)	1988-02-04	1989-08-10	Kyowa Hakko Kogyo Co., Ltd.	Derives de staurosporine
DE3835842A1 (de)	1988-10-21	1990-04-26	Goedecke Ag	Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE3924538A1 (de)	1989-07-25	1991-01-31	Goedecke Ag	Indolocarbazol und dessen verwendung
WO1991009034A1 (en)	1989-12-14	1991-06-27	Schering Corporation	Indolocarbazoles from saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951 atcc 53856
JPH0586068A (ja)	1991-03-04	1993-04-06	Rikagaku Kenkyusho	新規抗生物質ｒｋ−１４０９、その製造法並びに抗腫瘍剤及び抗炎症剤
WO1993008809A1 (en)	1991-11-08	1993-05-13	The University Of Southern California	Compositions containing k-252 compounds for potentiation of neurotrophin activity
JP2593021B2 (ja)	1991-12-13	1997-03-19	伊藤ハム株式会社	ウシ胚の性の識別方法
RU2045575C1 (ru) *	1992-01-29	1995-10-10	Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов	Рекомбинатная плазмидная днк ppr - tgatg - hil - 1 beta - tsr, обеспечивающая синтез рекомбинантного интерлейкина-1 и штамм escherichia coli - продуцент рекомбинантного интерлейкина-1 бета человека
US6271242B1 (en)	1992-02-10	2001-08-07	Bristol-Myers Squibb Co.	Method for treating cancer using a tyrosine protein kinase inhibitor
JPH05247055A (ja)	1992-03-03	1993-09-24	Meiji Seika Kaisha Ltd	スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
JPH0673063A (ja)	1992-06-22	1994-03-15	Kyowa Hakko Kogyo Co Ltd	Ｕｃｎ−０１誘導体
DE69326388T2 (de)	1992-06-22	1999-12-30	Kyowa Hakko Kogyo Co., Ltd.	Verfahren zur Herstellung von Staurosporin-Derivaten
US5461146A (en) *	1992-07-24	1995-10-24	Cephalon, Inc.	Selected protein kinase inhibitors for the treatment of neurological disorders
US5621100A (en)	1992-07-24	1997-04-15	Cephalon, Inc.	K-252a derivatives for treatment of neurological disorders
GB9215921D0 (en) *	1992-07-27	1992-09-09	Wellcome Found	Anti-inflammatory compounds
DE69409641T2 (de)	1993-05-28	1998-11-26	Cephalon, Inc., West Chester, Pa.	Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen
AU7000094A (en)	1993-06-17	1995-01-17	Ciba-Geigy Ag	Indolocarbazole compound useful as proteinkinase c inhibitor
AU1911095A (en)	1994-02-18	1995-09-04	Cephalon, Inc.	Aqueous indolocarbazole solutions

1997
- 1997-06-24 PT PT97930203T patent/PT912184E/pt unknown
- 1997-06-24 US US08/881,679 patent/US6184217B1/en not_active Expired - Lifetime
- 1997-06-24 RU RU99101117/14A patent/RU2183959C2/ru active
- 1997-06-24 EP EP97930203A patent/EP0912184B1/en not_active Expired - Lifetime
- 1997-06-24 ES ES97930203T patent/ES2184106T3/es not_active Expired - Lifetime
- 1997-06-24 AT AT97930203T patent/ATE224718T1/de active
- 1997-06-24 WO PCT/US1997/010898 patent/WO1997049406A1/en not_active Ceased
- 1997-06-24 NZ NZ333441A patent/NZ333441A/xx not_active IP Right Cessation
- 1997-06-24 BR BR9710693-3A patent/BR9710693A/pt not_active IP Right Cessation
- 1997-06-24 UA UA99010342A patent/UA65542C2/uk unknown
- 1997-06-24 DK DK97930203T patent/DK0912184T3/da active
- 1997-06-24 AU AU34090/97A patent/AU721942B2/en not_active Expired
- 1997-06-24 CN CN97197341A patent/CN1108799C/zh not_active Expired - Lifetime
- 1997-06-24 JP JP10503444A patent/JP2000514420A/ja active Pending
- 1997-06-24 DE DE69715862T patent/DE69715862T2/de not_active Expired - Lifetime
1998
- 1998-12-23 NO NO19986111A patent/NO317335B1/no not_active IP Right Cessation
2008
- 2008-03-04 JP JP2008053174A patent/JP4767982B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
UA65542C2 (uk)	2004-04-15
NO986111L (no)	1999-02-23
NZ333441A (en)	1999-05-28
JP2000514420A (ja)	2000-10-31
ATE224718T1 (de)	2002-10-15
EP0912184B1 (en)	2002-09-25
NO317335B1 (no)	2004-10-11
PT912184E (pt)	2002-12-31
US6184217B1 (en)	2001-02-06
AU721942B2 (en)	2000-07-20
AU3409097A (en)	1998-01-14
NO986111D0 (no)	1998-12-23
EP0912184A1 (en)	1999-05-06
RU2183959C2 (ru)	2002-06-27
JP4767982B2 (ja)	2011-09-07
HK1018745A1 (en)	2000-01-07
DK0912184T3 (da)	2002-11-25
WO1997049406A1 (en)	1997-12-31
BR9710693A (pt)	2000-01-11
DE69715862D1 (de)	2002-10-31
JP2008189676A (ja)	2008-08-21
DE69715862T2 (de)	2003-04-10
CN1108799C (zh)	2003-05-21
CN1228024A (zh)	1999-09-08

Publication	Publication Date	Title
ES2184106T3 (es)	2003-04-01	Utilizacion del derivado de k-252a en el tratamiento de trastornos del sistema nervioso periferico o central, y de la hiperproduccion de citoquinas.
MX9301634A (es)	1994-07-29	Quinuclidinas peptidicas.
DE69510940D1 (de)	1999-08-26	Pyrazolo und pyrrolopyridine
ES2132223T3 (es)	1999-08-16	Derivados de indol condensados en calidad de antagonistas del receptor 5-ht4.
LTPA2008008I1 (lt)	2021-02-25	Dipakeistieji bicikliniai heterociklai, jų produkcija ir panaudojimas kaip vaistų
DE59709414D1 (de)	2003-04-03	Oxyiminopregnancarbolactone
UA29466C2 (uk)	2000-11-15	Фармацевтична композиція з антипухлинною активністю
DK0520200T3 (da)	1998-09-23	Imadazol-forbindelser, deres fremstilling og anvendelse
EA200200742A1 (ru)	2002-12-26	1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии
ES2170798T3 (es)	2002-08-16	Benzopiranos y su uso como agentes terapeuticos.
ES2068714T3 (es)	1995-04-16	Derivados de pirimidina para aumentar la actividad antitumoral.
ES2166830T3 (es)	2002-05-01	Derivados 2,7-sustituidos de octahidro-1h-pirido(1,2-a)pirazina.
DE69604071D1 (de)	1999-10-07	Oxazolidinone derivate, ihre herstellung und ihre therapeutische verwendung
ES2153842T3 (es)	2001-03-16	Derivados de 3-oxo-pirido(1,2-a-)bencimidazol-4-carboxilo y de 4-oxo-azepino(1,2-a)bencimidazol-5-carboxilo utiles en el tratamiento de enfermedades del sistema nervioso central.
LV11940A (lv)	1998-01-20	Melatonina pielietojums personu arstesanai kuras cies no zalu atkaribas
ES2144857T3 (es)	2000-06-16	Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso.
NO970185L (no)	1997-03-12	Anvendelse av (S)-adenosyl-L-metionin (SAMe) og dets fysiologisk kompatible salter for behandling av reperfusjonsskade utlöst av temporær-fokal-ischemi
RU97113006A (ru)	1999-02-20	Штамм bacillus subtilis трас, резистентный к тетрациклину, рифампицину, ампициллину и стрептомицину, обладающий антибактериальной активностью по отношению к патогенным видам микроорганизмов
ES2173180T3 (es)	2002-10-16	Derivados del mercaptoacetilamida hipocolesterolemicos, antiateroescleroticos e hipotrigliceridemicos.
IT240104Y1 (it)	2001-03-26	Dispositivo per il trattamento del corpo umano.
ES2066897T3 (es)	1995-03-16	5,11-dihidro-6h-pirido(2,3-b)(1,4)benzodiazepin-6-onas y -tionas y su uso en la prevencion o el tratamiento del sida.
ES2163717T3 (es)	2002-02-01	Derivados de pirrolidinona y su uso como medicamentos antipsicoticos.
PT889044E (pt)	2005-01-31	Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
MX9204896A (es)	1993-02-01	Tiazepinas substituidas como agentes del sistema nervioso central.
AR021502A1 (es)	2002-07-24	Uso de derivados de azabicicloalcanos n-sustituidos para el tratamiento de enfermedades del sistema central nervioso